Guidelines for blood bank computing.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to D Gozzard.
Explore the source record for details and available documents.
A group of 13 patients with acute myeloid leukaemia of differing disease status were treated with continuous intravenous infusion of high-dose recombinant interleukin-2 (rIL-2). There was up-regulation of the cellular cytotoxic functions in all these patients following the rIL-2 therapy, with increase in the natural killer (NK) activity, lectin-dependent cellular cytotoxicity, induction of cytotoxicity-linked cytoplasmic serine esterase and lymphocyte activation. However, the clinical response to rIL-2 in these patients was disappointing, especially in patients treated in frank relapse. Although 1 patient treated in early second relapse achieved a third complete remission, the duration of the remission was brief and lasted only 6 months. Adverse reactions among these patients were common. Whether or not lymphokine-activated killer cells are needed to improve the response rate over rIL-2 alone in these patients deserves further investigation.
Hypomagnesaemia occurred in 6 of 11 leukaemic patients who received gentamicin. This problem has been reported relatively infrequently when gentamicin is used alone. Our hypomagnesaemic patients received concurrent courses of gentamicin with cytotoxic therapy significantly more often but it is not clear whether this represents a true drug interaction or an interaction between gentamicin and the products of cell lysis produced by cytotoxic treatment. The incidence of this problem has been underestimated previously because hypocalcaemia was used as an indicator. Renal wasting of magnesium is well documented as the mechanism by which the hypomagnesaemia is sustained but further investigation is required to see whether other factors are involved in its initiation.